Head to Head Review: Pluristem Therapeutics (PSTI) vs. Regulus Therapeutics (RGLS)
Pluristem Therapeutics (NASDAQ: PSTI) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.
Valuation & Earnings
This table compares Pluristem Therapeutics and Regulus Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pluristem Therapeutics||$2.85 million||54.86||-$27.81 million||($0.31)||-4.58|
|Regulus Therapeutics||$1.19 million||103.09||-$81.83 million||($1.35)||-0.87|
Risk and Volatility
Pluristem Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500.
This table compares Pluristem Therapeutics and Regulus Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations for Pluristem Therapeutics and Regulus Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pluristem Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 181.69%. Regulus Therapeutics has a consensus target price of $2.38, suggesting a potential upside of 101.27%. Given Pluristem Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Pluristem Therapeutics is more favorable than Regulus Therapeutics.
Institutional & Insider Ownership
4.5% of Pluristem Therapeutics shares are held by institutional investors. Comparatively, 57.8% of Regulus Therapeutics shares are held by institutional investors. 7.0% of Pluristem Therapeutics shares are held by insiders. Comparatively, 4.8% of Regulus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Pluristem Therapeutics beats Regulus Therapeutics on 10 of the 14 factors compared between the two stocks.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.